Annovis Bio’s oral therapy ANVS401 (also known as Posiphen) led to significant improvements in cognition in patients with Alzheimer’s disease, according to data from the first patient group in a Phase 2a study. The improvements were also observed in patients with Parkinson’s disease enrolled in the study. “The results from the first cohort of 14 [Alzheimer’s] and 14 [Parkinson’s] patients, show that the drug is effective in both diseases,” Maria L. Maccecchini, PhD, CEO of…
You must be logged in to read/download the full post.
The post ANVS401 Improves Cognition in Alzheimer’s and Parkinson’s, Data Show appeared first on BioNewsFeeds.